Skip to main content

Dr. Wasim E. Deeb, M.D.

Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)

  • Medicare participating

At a glance

Years since graduation
32
In the NPI registry since
2006
Medicare patients seen, 2024
853

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Endocrinology, Diabetes & Metabolism Physician primary
    FL license ME102044

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Endocrinology & Diabetes per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
853
Services billed
18,440
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, denosumab, 1 mg11,460116
Established patient office or other outpatient visit, 30-39 minutes1,430688
Injection of drug or substance under skin or into muscle660317
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg429224
Hemoglobin a1c level280210
Established patient office or other outpatient visit, 40-54 minutes202116
Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report18989
Blood glucose (sugar) test performed by hand-held instrument162128
New patient office or other outpatient visit, 45-59 minutes104104
New patient office or other outpatient visit, 60-74 minutes4040

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 37 companies reported 244 payments worth $37,978 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$28,453
Food and Beverage$5,518
Consulting Fee$2,790
Travel and Lodging$1,209
Education$7.80

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Mar 8, 2025Novo Nordisk Inc
Mar 8, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$5,504
May 15, 2025Novo Nordisk Inc
May 15, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$4,069
Apr 30, 2025Novo Nordisk Inc
Apr 30, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$3,023
Feb 28, 2025Cequr Corporation
Feb 28, 2025
Compensation for services other than consulting (speaking, faculty)
CeQur Simplicity · Diabetes
$2,275
Mar 25, 2025Amgen Inc.
Mar 25, 2025
Compensation for services other than consulting (speaking, faculty)
EVENITY · Bone Health
$2,200
Sep 25, 2025Amgen Inc.
Sep 25, 2025
Compensation for services other than consulting (speaking, faculty)
EVENITY · Bone Health
$2,200
Nov 13, 2025Novo Nordisk Inc
Nov 13, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$2,093
Oct 2, 2025Novo Nordisk Inc
Oct 2, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$2,093
Sep 4, 2025Novo Nordisk Inc
Sep 4, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$2,093
Sep 30, 2025Novo Nordisk Inc
Sep 30, 2025
Consulting Fee$1,395
All 19 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Nov 13, 2025Novo Nordisk Inc
Nov 13, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$2,093
Nov 12, 2025Ascendis Pharma Endocrinology Inc
Nov 12, 2025
Education
Yorvipath · Endocrinology · in-kind
$7.80
Oct 7, 2025Novo Nordisk Inc
Oct 7, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$494
Oct 2, 2025Novo Nordisk Inc
Oct 2, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$2,093
Sep 30, 2025Novo Nordisk Inc
Sep 30, 2025
Consulting Fee$1,395
Sep 29, 2025Novo Nordisk Inc
Sep 29, 2025
Consulting Fee$1,395
Sep 25, 2025Amgen Inc.
Sep 25, 2025
Compensation for services other than consulting (speaking, faculty)
EVENITY · Bone Health
$2,200
Sep 4, 2025Novo Nordisk Inc
Sep 4, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$2,093
Aug 29, 2025Novo Nordisk Inc
Aug 29, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$930
May 20, 2025Novo Nordisk Inc
May 20, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$930
May 15, 2025Novo Nordisk Inc
May 15, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$4,069
May 15, 2025Novo Nordisk Inc
May 15, 2025
Travel and Lodging
Ozempic · Diabetes · travel to Palm Coast, FL · in-kind
$753
Apr 30, 2025Novo Nordisk Inc
Apr 30, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$3,023
Mar 25, 2025Amgen Inc.
Mar 25, 2025
Compensation for services other than consulting (speaking, faculty)
EVENITY · Bone Health
$2,200
Mar 8, 2025Novo Nordisk Inc
Mar 8, 2025
Compensation for services other than consulting (speaking, faculty)
Ozempic · Diabetes
$5,504
Mar 8, 2025Novo Nordisk Inc
Mar 8, 2025
Travel and Lodging
Ozempic · Diabetes · travel to Orlando, FL · in-kind
$399
Mar 8, 2025Novo Nordisk Inc
Mar 8, 2025
Travel and Lodging
Ozempic · Diabetes · travel to Orlando, FL · in-kind
$57.51
Feb 28, 2025Cequr Corporation
Feb 28, 2025
Compensation for services other than consulting (speaking, faculty)
CeQur Simplicity · Diabetes
$2,275
Feb 10, 2025Amgen Inc.
Feb 10, 2025
Compensation for services other than consulting (speaking, faculty)
EVENITY · Bone Health
$551

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 13 industry-funded studies in 2025, from 10 companies. The companies reported $597,413 in research payments for these studies, mostly to the institutions running them.

  • A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
    AbbVie Inc. · Active, not recruiting · NCT06345339
  • A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight…
    AstraZeneca UK Limited
  • A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
    Novartis Pharmaceuticals Corporation
  • M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
    AbbVie Inc.
  • A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients…
    Alnylam Pharmaceuticals Inc.
  • A phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure…
    AstraZeneca Pharmaceuticals LP
  • A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
    AbbVie Inc.
  • ISM2411001A--Prolongation of GLP-1 Adherence when using Continuous Glucose Monitoring
    Abbott Laboratories
  • A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
    Boehringer Ingelheim Pharma GmbH & Co.kg

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Endocrinology & Diabetes clinicians in Jacksonville

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 23, 2019), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1881700698. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.